E. A. Egorov

E. A. Egorov

Auto-generated profile, based on publicly available information

E. A. Egorov

Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2016 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
OBOlga V. Britanova
Olga V. Britanova
MSMikhail Shugay
Mikhail Shugay
EMEkaterina Merzlyak
Ekaterina Merzlyak
DSDmitry Staroverov
Dmitry Staroverov
EPEkaterina V. Putintseva
Ekaterina V. Putintseva
DCDmitriy M. Chudakov
Dmitriy M. Chudakov
The diversity, architecture, and dynamics of the TCR repertoire largely determine our ability to effectively withstand infections and malignancies with minimal mistargeting of immune responses. In this study, we have employed deep TCRβ repertoire sequencing with normalization based on unique molecular identifiers to explore the long-term dynamics of T cell immunity. We demonstrate remarkable stability of repertoire, where approximately half of all T cells in peripheral blood are represented by clones that persist and generally preserve their frequencies for 3 y. We further characterize the extremes of lifelong TCR repertoire evolution, analyzing samples ranging from umbilical cord blood to centenarian peripheral blood. We show that the fetal TCR repertoire, albeit structurally maintained within regulated borders due to the lower numbers of randomly added nucleotides, is not limited with respect to observed functional diversity. We reveal decreased efficiency of nonsense-mediated mRNA decay in umbilical cord blood, which may reflect specific regulatory mechanisms in development. Furthermore, we demonstrate that human TCR repertoires are functionally more similar at birth but diverge during life, and we track the lifelong behavior of CMV- and EBV-specific T cell clonotypes. Finally, we reveal gender differences in dynamics of TCR diversity constriction, which come to naught in the oldest age. Based on our data, we propose a more general explanation for the previous observations on the relationships between longevity and immunity.

16 June 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NLNadezhda N. Logunova
Nadezhda N. Logunova
VKValeriia V. Kriukova
Valeriia V. Kriukova
PSPavel V. Shelyakin
Pavel V. Shelyakin
EEEvgeny S. Egorov
Evgeny S. Egorov
APAlina Pereverzeva
Alina Pereverzeva
OBOlga Britanova
Olga Britanova
T cell maturation and activation depend upon T cell receptor (TCR) interactions with a wide variety of antigenic peptides displayed in a given major histocompatibility complex (MHC) context. Complementarity-determining region 3 (CDR3) is the most variable part of the TCRα and -β chains, which govern interactions with peptide–MHC complexes. However, it remains unclear how the CDR3 landscape is shaped by individual MHC context during thymic selection of naïve T cells. We established two mouse strains carrying distinct allelic variants ofH2-Aand analyzed thymic and peripheral production and TCR repertoires of naïve conventional CD4+T (Tconv) and naïve regulatory CD4+T (Treg) cells. Compared with tuberculosis-resistant C57BL/6 (H2-Ab) mice, the tuberculosis-susceptible H2-Ajmice had fewer CD4+T cells of both subsets in the thymus. In the periphery, this deficiency was only apparent for Tconvand was compensated for by peripheral reconstitution for Treg. We show that H2-Ajfavors selection of a narrower and more convergent repertoire with more hydrophobic and strongly interacting amino acid residues in the middle of CDR3α and CDR3β, suggesting more stringent selection against a narrower peptide–MHC-II context. H2-Ajand H2-Abmice have prominent reciprocal differences in CDR3α and CDR3β features, probably reflecting distinct modes of TCR fitting to MHC-II variants. These data reveal the mechanics and extent of how MHC-II shapes the naïve CD4+T cell CDR3 landscape, which essentially defines adaptive response to infections and self-antigens.

1 January 2022 in Russian Annals of Ophthalmology
Verified
Journal Article
Closed access
AMA.B. Movsisyan
A.B. Movsisyan
JOJanna G. Oganezova
Janna G. Oganezova
EEE.A. Egorov
E.A. Egorov
Развитие диагностических технологий в медицине, в частности в офтальмологии, позволило изучить человеческий глаз не только на гистологическом, но и на клеточном уровне. Роль нервной системы в работе зрительного анализатора связана не только с обеспечением двигательной, защитной и сенсорной функций, а прежде всего, с обеспечением самого зрительного процесса. Нейродегенеративные заболевания занимают особое место среди системных патологий. В настоящее время развитие данного процесса связывают с нейровоспалением, роль которого подтверждена и при глаукоме. По этой причине достижение целевого уровня внутриглазного давления не всегда гарантирует стабилизацию дегенеративного процесса. Ввиду этого препараты-нейропротекторы рекомендуется применять у любого пациента с глаукомой с учетом особенностей патогенеза заболевания. Благодаря своим антиоксидантным и нейропротекторным свойствам этилметилгидроксипиридина сукцинат (Мексидол) широко используется в офтальмологической практике, в частности при лечении пациентов с глаукомной оптической нейропатией и заболеваниями сетчатки. Результаты исследований продемонстрировали эффективность Мексидола в отношении замедления нейродегенерации и стабилизации зрительных функций у больных первичной открытоугольной глаукомой благодаря антигипоксантным, антиоксидантным и мембраностабилизирующим свойствам препарата и его положительному влиянию на нейромедиаторный баланс и глазной кровоток.

31 March 2024 in Ophthalmology in Russia
Verified
Journal Article
Open access
PDF file
JOJanna G. Oganezova
Janna G. Oganezova
VKVitaly V. Kadyshev
Vitaly V. Kadyshev
EEE. A. Egorov
E. A. Egorov
This publication continues a review published in December 2023 about the genetic epidemiology and genotype-phenotype correlations in primary congenital glaucoma (PCG) worldwide, and presents data from East and South Asia, Western Europe and Russia. Analysis of the incidence of PCG data in these regions shows that the rates for Western Europe, the European part of Russia and East Asia are comparable and average 1:10,000–18,000 newborns and higher in ethnically mixed groups. On the territory of South Asia, the minimum number of children with PCG was recorded in Nepal, and the maximum in India. The majority of researchers talk about the predominance of bilateral process in 62 to 99 % cases. As a rule, there is a slight predominance of boys among patients with PCG; authors from India and France report approximately the same number of boys and girls, and German scientists have found a higher prevalence of PCG among girls. If we talk about the phenotype of the disease, almost all researchers note a more severe course in subgroups with the presence ofCYP1B1mutations than in patients who do not have a mutation in this gene. As for the genetic causes of PCG, the most common are mutations in theCYP1B1gene, accounting for up to a third of cases in India, Pakistan, Western Europe and the European part of Russia. In East Asian patients, mutations in theCYP1B1gene are most likely not the main ones in the pathogenesis of PCG, because are found much less frequently and often only in one allele. Chinese scientists say that it is necessary to pay attention to mutationsTEKandZC2HC1C,VPS13D,PGF.

27 December 2023 in Ophthalmology in Russia
Verified
Journal Article
Open access
PDF file
JOJanna G. Oganezova
Janna G. Oganezova
VKVitaly V. Kadyshev
Vitaly V. Kadyshev
EEE. A. Egorov
E. A. Egorov
To understand the current situation with the genetic epidemiology of primary congenital glaucoma (PCG) in the world, as well as to identify genotype-phenotype correlations, 87 publications were analyzed from the Pubmed and elibrary databases, mainly the latest 5 years. This publication presents the first part of the analysis, covering Arab and African countries, Turkey, the USA, Brazil, Australia and New Zealand. The second part of the review, which will be published in early 2024, will focus on data from East and South Asia, Western Europe and Russia. The highest incidence of PCG is typical for Arab countries, which is associated with the presence of a significant number of consanguineous marriages in these countries. In most countries, boys predominated among patients with PCG, and the process was often bilateral. In Australia female patients predominate. The PCG phenotype is more severe in patients with CYP1B1 mutations (early onset, bilateral involvement) than in patients without mutations, and in patients with consanguineous parents than in children from unrelated marriages. Among the genetic causes of PCG in different populations, the most common (from 30 to 86 % of cases) in Arab countries, Brazil and Turkey are mutations in the CYP1B1 gene. The spectrum of mutations varies depending on the region. In Australia and New Zealand, biallelic mutations were identified in the CYP1B1, CPAMD8 and COL18A1 genes, as well as heterozygous mutations in the TEK, FOXC1 and ANGPT1. Mutations in rare genes were also found in patients with PCG from Lebanon (ANGPT1 (p.K186N), Mauritania (NTF4 (c.601T>G, p.Cys201Gly) and WDR36 (c.2078A>G, p.Asn693Ser)). In the USA, the influence of the thrombospondin gene (THBS1) on the development of PCG is being studied. Based on the results of genetic and epidemiological studies, specific treatment, rehabilitation and preventive programs can be developed, which will determine the success of PCG therapy in children, preserving their visual functions.

8 September 2025 in Russian Annals of Ophthalmology
Verified
Journal Article
Closed access
EEE.A. Egorov
E.A. Egorov
AKA.V. Kuroyedov
A.V. Kuroyedov
NGN.A. Gavrilova
N.A. Gavrilova
AYA.E. Yavorskiy
A.E. Yavorskiy
EGE.A. Gornostaeva
E.A. Gornostaeva
Objective. This study evaluated the effect of sequential therapy with different dosages of Mexidol on the stabilization of glaucomatous optic neuropathy (GON) in patients with primary open-angle glaucoma (POAG). Material and methods. The study included 80 patients (160 eyes) with stage II and III POAG, randomized into three groups comparable by age, gender, and distribution of glaucoma stage. All patients received sequential therapy with Mexidol (14 days parenterally followed by 90 days orally). Groups were defined as follows: group 1 — “high dosage”, group 2 — “low dosage”, and group 3 — “placebo”. Before therapy initiation and at completion, static automated perimetry was used to determine the mean deviation (MD) and pattern standard deviation (PSD) of retinal light sensitivity, as well as the number of first- and second-order scotomas. Subgroup analysis was performed based on treatment response. Glaucoma progression during therapy was analyzed using the Kaplan-Meier method. Results. A statistically significant improvement in MD compared with baseline was observed after the course of therapy in both the high- and low-dose groups for moderate (p<0.001) and advanced (p<0.05) stages of POAG. There was a trend toward PSD improvement in the groups of both dosages, but absent in the placebo group. Unlike the treatment groups, the placebo group showed a negative trend toward an increase in relative first- and second-order scotomas. Subgroup comparison revealed significant differences among the “high dosage”, “low dosage”, and “placebo” groups (p=0.002, Pearson’s χ² test). Kaplan-Meier analysis demonstrated a high probability of glaucoma progression in the “placebo” group and a significantly lower probability (p<0.01) in both “high dosage” and “low dosage” Mexidol groups. Conclusion. Mexidol therapy improves retinal light sensitivity, stabilizes the number of relative first- and second-order scotomas, and reduces the likelihood of GON progression. The dose-dependent effect of Mexidol was demonstrated.